New - European Medical Journal

Continue

News

Rheumatology
17 Jun 2016

New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio

June 09, 2016 07:08 AM Eastern Daylight Time ZUG, Switzerland–(BUSINESS WIRE)–Data demonstrating long-term comparable efficacy, safety and immunogenicity…
Oncology
13 Jun 2016

Daratumumab (DARZALEX®) Combination Therapy Significantly Extended Progression-Free Survival in Previously Treated Patients with Multiple Myeloma

Beerse, Belgium, 5 June 2016 – Data from the Phase 3 MMY3004 (CASTOR) clinical trial show the immunotherapy daratumumab (DARZALEX®) in combination with a…
Oncology
13 Jun 2016

Helsinn Group Hosts a Satellite Symposium on Shared Decision Making in Supportive Care, at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Annual Meeting 2016 on June 24th

Lugano, Switzerland, June 13, 2016 – Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that it is…
EMJ
Reproductive Health
13 Jun 2016

Prehistoric Protein Could Hold the Key to Improving Treatments for Miscarriage

PIONEERING research in stem cell biology has discovered that a protein evolved from a viral infection in primates 25 million years ago may enhance…
EMJ
Reproductive Health
13 Jun 2016

Seeing Double: Genes Increasing the Likelihood of Dizygotic Twins Discovered

A BREAKTHROUGH in the genetics of twinning has been made with the recent identification of genes that increase the prospect of dizygotic (DZ) twins, a…
Neurology
10 Jun 2016

New Janssen Phase 3 Data in Patients with Moderately to Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression and Improves Signs and Symptoms of Disease

London, United Kingdom, 8 June, 2016 – Janssen Research & Development, LLC (Janssen) announced today results from a pivotal Phase 3 study evaluating…
Rheumatology
10 Jun 2016

New Data Demonstrates Sandoz’ Etanercept and Rituximab Biosimilar Candidates Bioequivalent to Originator Products

Holzkirchen, June 9 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from two key studies…
EMJ
Allergy & Immunology
9 Jun 2016

T Cell Protein Provides New Leads in Understanding Immune Response

AN INNOVATIVE new study has uncovered a protein that is fundamental to controlling immune responses, which could provide much needed clarification of…